Minimal added value of wetting hair before scalp cooling to prevent chemotherapy-induced alopecia in cancer patients — results from the Dutch Scalp Cooling Registry

Heibloem, Robin E; Komen, M.M.C.; Ilozumba, Onaedo; Hurk, Corina van den

doi:10.1007/s00520-023-07687-6

Cited by 2 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, despite these efforts, there are currently no established preventive measures for OM or dysgeusia. Thus, this retrospective study aimed to identify factors for the development of OM or dysgeusia in breast cancer patients treated with 5-uorouracil 500 mg/m², epirubicin 100 mg/m², and cyclophosphamide 500 mg/m² (FEC) every 3 weeks for four cycles [17][18][19]. The ultimate goal was to facilitate the development of targeted strategies aimed at improving the QoL of patients undergoing chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Factors related to oral mucositis or dysgeusia in breast cancer patients undergoing fluorouracil, epirubicin, and cyclophosphamide therapy: A single-center, retrospective study

Kanbayashi,

Taguchi,

Ishikawa

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose: This retrospective study aimed to identify factors contributing to the development of oral mucositis (OM) or dysgeusia. Methods: Between February 2016 and September 2020, 154 female breast cancer patients undergoing chemotherapy with fluorouracil, epirubicin, and cyclophosphamide were enrolled at our outpatient chemotherapy center. Variables related to the development of OM or dysgeusia were extracted from the patients’ medical records. The severity of OM or dysgeusia was assessed at the end of chemotherapy using a questionnaire designed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5. Multivariate ordered logistic regression analysis was performed. Results: Factors significantly correlated with the development of OM included age (odds ratio [OR] = 1.04, 95% confidence interval [CI] = 1.01-1.07; P = 0.025), number of cycles (OR = 1.60, 95% CI = 1.02-2.51; P = 0.042), non-steroidal anti-inflammatory drugs (NSAIDs) (OR = 4.52, 95% CI = 1.05-19.51;P = 0.043), mucoprotective agents (OR = 2.82, 95% CI = 1.24-6.45; P= 0.014), and palliative chemotherapy (OR = 0.09, 95% CI = 0.01-0.60; P= 0.013). Factors significantly correlated with the development of dysgeusia were albumin (OR = 0.46, 95% CI = 0.21- 0.998; P = 0.049) and palliative chemotherapy (OR = 0.14, 95% CI = 0.03- 0.68; P = 0.015). Although not significant, potential prophylactic factors were statins for OM and renin-angiotensin system inhibitors for dysgeusia. Conclusions: The identified factors for OM or dysgeusia may help develop strategies to improve the quality of life of patients receiving chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Factors related to oral mucositis or dysgeusia in breast cancer patients undergoing fluorouracil, epirubicin, and cyclophosphamide therapy: A single-center, retrospective study

Kanbayashi,

Taguchi,

Ishikawa

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Electric hand warmer versus observation to avoid discomfort during scalp cooling for chemotherapy-induced alopecia prevention: a randomized study

Landeiro,

Lopes Paim Miranda,

Mathias Machado

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Chemotherapy-induced alopecia (CIA) is a challenge in the management of cancer patients. Scalp cooling (SC) leads to reduction in CIA, however it is associated with significant adverse events, leading to 3–13% discontinuation rates. This pilot study evaluated the role of Electric Hand Warmers (EHW) on thermal (TC), sensorial (SCo) and general comfort (GC) in patients with breast cancer (BC) undergoing chemotherapy and SC to reduce CIA. Patients were randomly assigned to EHW use or observation. TC, SCo and GC were evaluated after each chemotherapy infusion. Favorable outcomes in both TC and SCo defined a positive result on GC. We analysed the impact of age, alopecia, chemotherapy regimen and EHW use in the different comfort scales using a Logistic Regression (LR) model. Forty women with early breast cancer were randomly assigned to EHW (n = 20) or observation (n = 20) during neo(adjuvant) chemotherapy. Median age was 53 years. In the EHW arm, favorable thermal response was reported by 79% versus 50% in the control arm (odds ratio [OR] 3.79, p < 0.001). SCo was satisfactory in 82% in the EHW arm versus 74% in the control arm (OR 1.62, p = 0.1). Overall, 73% in the EHW arm had favorable GC versus 44% in the control arm (OR 3.4, p < 0.001). Age, alopecia, and chemotherapy regimen did not impact on comfort measures. Conclusion: Our study suggests that the use of an EHW has a consistent favorable impact on TC and GC of BC patients under SC technology to prevent CIA.

show abstract

Minimal added value of wetting hair before scalp cooling to prevent chemotherapy-induced alopecia in cancer patients — results from the Dutch Scalp Cooling Registry

Cited by 2 publications

References 36 publications

Factors related to oral mucositis or dysgeusia in breast cancer patients undergoing fluorouracil, epirubicin, and cyclophosphamide therapy: A single-center, retrospective study

Factors related to oral mucositis or dysgeusia in breast cancer patients undergoing fluorouracil, epirubicin, and cyclophosphamide therapy: A single-center, retrospective study

Electric hand warmer versus observation to avoid discomfort during scalp cooling for chemotherapy-induced alopecia prevention: a randomized study

Contact Info

Product

Resources

About